One caveat of our study is that the subcutaneous model may not fully recapitulate the TIME and provide high translational result akin to orthotopic models.[51] However, this should not detract from our conclusion that sustained intratumoral delivery of CD40 mAb is a viable approach to replace systemic administration for effective anti‐tumor activity and reduced toxicity in PDAC. Here, CD40 is linked to neoplasm.